



1635

Attorney Docket No. 44342.011800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: HIRABAYASHI, K., et al

SERIAL NO.: 09/646,135

Group Art Unit: 1635

FILED: September 8, 2000

Examiner: WHITEMAN, B.

FOR: REMEDIES FOR HEPATITIS

AMENDMENT AND RESPONSE UNDER 37 CFR 1.111

In response to the USPTO Official Action mailed on July 17, 2002, please amend the above-identified application as follows:

In the Specification

On page 12, please delete the third full paragraph and, in lieu thereof, please insert the following:

A1 It is apparent from Figure 1 that every sample expressed β -interferon mRNA and that β -interferon was induced in a dose-depending manner. The agent of present invention induced more β -interferon than the poly (I) poly (C) alone did.

On page 12, please delete the fourth full paragraph and, in lieu thereof, please insert the following:

A2 The amount of expressed β -interferon mRNA in mouse tissues other than liver was determined in the same manner as Text Example 1. The result is shown in Figure 2.

RECEIVED
NOV 05 2002
TECH CENTER 1600/2900